Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 10:10:1234.
doi: 10.3389/fneur.2019.01234. eCollection 2019.

Use of Fatigue Index as a Measure of Local Muscle Fatigability in Ryanodine Receptor Isoform-1-Related Myopathies

Affiliations

Use of Fatigue Index as a Measure of Local Muscle Fatigability in Ryanodine Receptor Isoform-1-Related Myopathies

Jessica W Witherspoon et al. Front Neurol. .

Abstract

Introduction: Individuals affected with ryanodine receptor isoform-1-related myopathies (RYR1-RM) commonly experience fatigability in the quadriceps, which may limit physical function and potentially diminish quality of life. Fatigability, in RYR1-RM, results from skeletal muscle injury secondary to dysfunction of the major skeletal muscle Ca++ channel. However, during fatigability testing, affected individuals did not always reach the point of local muscle fatigue as defined by a fatigue index (FATI) at 50% of peak torque. Surakka et al. compared three versions of FATI equations, which vary by the area under the force curve (AUC). By performing this comparison, they were able to determine the optimal equation in individuals with Multiple Sclerosis. Purpose: Using a similar comparison, we sought to identify the optimal FATI equation in the RYR1-RM population. Secondly, because local muscle fatigability might have an impact on independent living, this study also assessed change in local muscle fatigability over a 6-month time frame. Methods: Thirty participants were analyzed from the RYR1-RM natural history study and double-blind, placebo-controlled N-acetylcysteine (NAC) trial, NCT02362425. Twenty-seven had fatigability data, from isometric knee extension and flexion fatigability tests, available for the purpose of establishing a method for predicting FATI at 50% peak torque. For the natural history study, 30 participants were used to assess disease progression of local muscle fatigability achieved during the knee extension fatigability test, and 29 participants for the knee flexion fatigability test. Results: Surakka's equation 1, using the prediction approach, led to the smallest median error, the smallest square-root of uncorrected sum of squares, and the smallest average of the absolute value of the differences. No difference was observed in FATI at 50% peak torque between month 0 and month 6 for extension (p = 0.606) and flexion (p = 0.740). Conclusion: Surakka's equation 1, with the prediction approach, was found to be the most accurate for imputing values when fatigue was not reached during a sustained knee isometric fatigability test in RYR1-RM. Furthermore, when used to assess fatigability-based disease stability, local muscle fatigability, in this RYR1-RM population remained stable.

Keywords: RYR1-RM; fatigability; fatigue index; muscle; neuromuscular.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diagram of participants and observations used for analysis. Natural history (section Fatigability Testing); predicting FATI (section Prediction Method for FATI); disease progression (section Disease Progression).
Figure 2
Figure 2
Testing set (Biodex 3 Medical Systems Inc., Shirley, NY, USA).
Figure 3
Figure 3
Comparative analyses of predicted FATI at 50% peak torque using Approach 1 (section Approach 1) and actual FATI at 50% peak torque for extension and flexion. Result: observations aggregate together relative to linear line.
Figure 4
Figure 4
Comparative analyses of predicted FATI at 50% peak torque using Approach 2 (section Approach 2) and actual FATI at 50% peak torque for extension and flexion. Result: observations are spread apart relative to linear line.

Similar articles

References

    1. van Ruitenbeek E, Custers JAE, Verhaak C, Snoeck M, Erasmus CE, Kamsteeg EJ, et al. . Functional impairments, fatigue and quality of life in RYR1-related myopathies: a questionnaire study. Neuromusc Disord. (2019) 29:30–8. 10.1016/j.nmd.2018.10.006 - DOI - PubMed
    1. Arafah A, Kuspinar A, Mayo N. Untangling perception of fatigue and fatigability: first steps. Austin J Multiple Scleros Neuroimmunol. (2015) 2:1018–25.
    1. Surakka J, Virtanen A, Aunola S, Mäentaka K, Pekkarinen H. Reliability of knee muscle strength and fatigue measurements. Biol Sport. (2005) 22:301–13.
    1. Witherspoon JW, Meilleur KG. Review of RyR1 pathway and associated pathomechanisms. Acta Neuropathol Commun. (2016) 4:121. 10.1186/s40478-016-0392-6 - DOI - PMC - PubMed
    1. Montes J, Blumenschine M, Dunaway S, Alter AS, Engelstad K, Rao AK. Weakness and fatigue in diverse neuromuscular diseases. J Child Neurol. (2013) 28:1277–83. 10.1177/0883073813493663 - DOI - PubMed

LinkOut - more resources